Home LiteratureArticle Details
PMID: 9124836 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

Antimicrobial agents and chemotherapy ·Vol. 40 ·No. 12 ·1996-12-00 ·Pages 2760-4

Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L

Abstract

The mechanism of high-level fluoroquinolone resistance was studied in strains of Streptococcus pneumoniae, either selected in vitro or isolated from clinical samples. By using DNA from these high-level-resistant strains, low-level-resistant transformants (MIC of pefloxacin, > or = 32 micrograms/ml; MIC of ciprofloxacin, 4 micrograms/ml; MIC of sparfloxacin, 0.50 micrograms/ml) were obtained at high frequencies (ca.10(-2)), while high-level-resistant transformants (MIC of pefloxacin, > or = 64 micrograms/ml; MIC of ciprofloxacin, 16 to 64 micrograms/ml; MIC of sparfloxacin, > or = 8 micrograms/ml) were obtained only at low frequencies (ca.10(-4)). This suggested that mutations in at least two unlinked genes were necessary to obtain high-level resistance. Low-level resistance was associated with ParC mutations (change from Ser to Tyr at position 79 [Ser79Tyr], Ser79Phe, or Asp83Gly). ParC mutations were associated, in high-level-resistant strains and transformants, with alterations in the quinolone resistance-determining region of GyrA (Ser84Tyr, Ser84Phe, and/or Glu88Lys). Low-level resistance was shown to be necessary for expression of the gyrA mutations. No mutation in the region corresponding to the quinolone resistance-determining region of GyrB and no alteration of drug accumulation were found.

MeSH Terms
4-Quinolones Anti-Infective Agents/pharmacology Ciprofloxacin/pharmacology DNA Gyrase DNA Topoisomerase IV DNA Topoisomerases, Type II/genetics Drug Resistance, Microbial/genetics Fluoroquinolones Genes, Bacterial/drug effects,genetics Mutation Quinolones/pharmacology Sequence Analysis, DNA Streptococcus pneumoniae/drug effects,genetics Transformation, Genetic
Chemicals
4-Quinolones Anti-Infective Agents Fluoroquinolones Quinolones perfloxacin Ciprofloxacin DNA Topoisomerase IV DNA Gyrase DNA Topoisomerases, Type II sparfloxacin
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Janoir C
L.R.M.A., Université Paris VI, France.
Zeller V
Kitzis M D
Moreau N J
Gutmann L
References (38)
38 references, click to expand
  1. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    J Bacteriol. 1996 Jul;178(14):4060-9 PMID: 8763932
  2. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
    Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):304-15 PMID: 1864291
  3. Marker discrimination in transformation and mutation of pneumococcus.
    Proc Natl Acad Sci U S A. 1973 Dec;70(12):3541-5 PMID: 4148702
  4. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
    Chemotherapy. 1993;39(1):36-9 PMID: 8383031
  5. Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins.
    J Bacteriol. 1992 Mar;174(5):1596-603 PMID: 1311298
  6. In Vivo Selection of Streptococcus pneumoniae, Resistant to Quinolones, Including Sparfloxin.
    Clin Microbiol Infect. 1995 Sep;1(1):60-61 PMID: 11866724
  7. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.
    Antimicrob Agents Chemother. 1995 Jul;39(7):1554-8 PMID: 7492103
  8. Quinolone-resistant mutations of the gyrA gene of Escherichia coli.
    Mol Gen Genet. 1988 Jan;211(1):1-7 PMID: 2830458
  9. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
    J Antimicrob Chemother. 1990 Nov;26(5):667-76 PMID: 2079449
  10. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.
    Eur J Clin Microbiol Infect Dis. 1990 Dec;9(12):905-6 PMID: 2073905
  11. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Mol Microbiol. 1994 Aug;13(4):641-53 PMID: 7997176
  12. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.
    Antimicrob Agents Chemother. 1994 Sep;38(9):2014-23 PMID: 7811012
  13. Dissociated resistance among fluoroquinolones.
    Antimicrob Agents Chemother. 1994 Sep;38(9):2095-100 PMID: 7811025
  14. Mechanisms of resistance to quinolones.
    Drugs. 1993;45 Suppl 3:15-23 PMID: 7689446
  15. Cloning, sequencing, and expression of the DNA gyrase genes from Staphylococcus aureus.
    J Bacteriol. 1993 Jun;175(11):3269-77 PMID: 8388872
  16. A study of the genetic material determining an enzyme in Pneumococcus.
    Biochim Biophys Acta. 1960 Apr 22;39:508-18 PMID: 14413322
  17. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.
    Antimicrob Agents Chemother. 1991 Aug;35(8):1647-50 PMID: 1656869
  18. Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition.
    J Antimicrob Chemother. 1993 Sep;32(3):379-92 PMID: 8262860
  19. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus.
    J Infect Dis. 1991 May;163(5):1080-6 PMID: 1850442
  20. The selection and frequency of streptococci with decreased susceptibility to ofloxacin compared with other quinolones.
    J Antimicrob Chemother. 1988 Sep;22 Suppl C:45-51 PMID: 3182461
  21. Antimicrobial resistance in Streptococcus pneumoniae: an overview.
    Clin Infect Dis. 1992 Jul;15(1):77-83 PMID: 1617076
  22. Release of genetic transforming agent from pneumococcal cultures during growth and disintegration.
    J Exp Med. 1962 Oct 1;116:491-519 PMID: 13940741
  23. In vitro activity of sparfloxacin compared with those of five other quinolones.
    Antimicrob Agents Chemother. 1992 Mar;36(3):558-65 PMID: 1320362
  24. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.
    Antimicrob Agents Chemother. 1996 Apr;40(4):879-85 PMID: 8849244
  25. Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance.
    J Bacteriol. 1995 Jul;177(14):4166-70 PMID: 7608096
  26. Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis.
    Antimicrob Agents Chemother. 1994 Sep;38(9):2091-4 PMID: 7811024
  27. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae.
    Antimicrob Agents Chemother. 1995 Feb;39(2):561-3 PMID: 7726535
  28. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.
    Antimicrob Agents Chemother. 1990 Jun;34(6):1271-2 PMID: 2168148
  29. Donor deoxyribonucleic acid length and marker effect in pneumococcal transformation.
    J Bacteriol. 1979 Apr;138(1):80-6 PMID: 35523
  30. Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis.
    Antimicrob Agents Chemother. 1991 Oct;35(10):2151-4 PMID: 1662027
  31. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli.
    Mol Gen Genet. 1986 Sep;204(3):367-73 PMID: 3020376
  32. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.
    Antimicrob Agents Chemother. 1986 Apr;29(4):639-44 PMID: 3010850
  33. Topoisomerase IV is a target of quinolones in Escherichia coli.
    Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11801-5 PMID: 8524852
  34. Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing.
    Antimicrob Agents Chemother. 1992 May;36(5):1166-9 PMID: 1510411
  35. Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones.
    Antimicrob Agents Chemother. 1995 Jul;39(7):1414-8 PMID: 7492077
  36. Nucleotide sequences of the pbpX genes encoding the penicillin-binding proteins 2x from Streptococcus pneumoniae R6 and a cefotaxime-resistant mutant, C506.
    Mol Microbiol. 1989 Oct;3(10):1337-48 PMID: 2615650
  37. In vitro studies of ciprofloxacin and survey of resistance patterns in current isolates.
    Diagn Microbiol Infect Dis. 1990 Mar-Apr;13(2):79-91 PMID: 2369816
  38. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates.
    Mol Microbiol. 1994 Oct;14(2):371-80 PMID: 7830580
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1996-12-00
Pages
2760-4
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC163617
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com